# US 2024/0189523 A1 · Hot porous-solid metering systems and methods for generation of therapeutic aerosols by evaporation/condensation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189523 A1
- Document ID: US20240189523A1
- Status: Published application
- Kind: A1
- Application number: 18/286,695
- Filed: 2022-04-14
- Published: 2024-06-13
- Earliest claimed: 2021-04-14
- Assignees: The University of North Carolina at Chapel Hill; Research Triangle Institute
- Applicants: The University of North Carolina at Chapel Hill; Research Triangle Institute
- Inventors: Anthony James HICKEY; Ian Edward STEWART
- Web page: https://patentgrep.com/patent/US20240189523A1

## CPC

- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61M 11/042: {electrical}
- A61M 11/005: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 15/0021: {Mouthpieces therefor}
- A61M 15/0065: {Inhalators with dosage or measuring devices (A61M15/0028 takes precedence; dosage devices incorporated in aerosol cans B65D83/52)}
- A61M 2016/0021: {with a proportional output signal, e.g. from a thermistor}
- A61M 2016/0027: {pressure meter}
- A61M 2205/3592: using telemetric means, e.g. radio or optical transmission
- A61M 2205/3653: by Joule effect, i.e. electric resistance
- A61M 2205/52: with memories providing a history of measured variating parameters of apparatus or patient
- A61M 2205/6045: having complementary physical shapes for indexing or registration purposes
- A61M 2205/8206: battery-operated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Devices and methods for generating an aerosol of a therapeutic agent and methods of using and preparing the same are disclosed. The device includes a heatable porous substrate (e.g., a porous metal or metal alloy) embedded with a composition containing a vaporizable carrier compound (e.g., a phospholipid) and at least one therapeutic agent. The device can be incorporated into a delivery device, such as a metered dose inhaler or an exposure chamber. When the heatable porous substrate is heated, such as by resistive heating, the carrier compound is vaporized and both it and the at least one therapeutic agent are carried out of the porous substrate and, upon cooling, form aerosol particles comprising the at least one therapeutic agent.

## Claims

### Claim 1

A device for aerosol generation comprising:
a substrate comprising a porous material having a plurality of pores distributed throughout the substrate; and
a composition, which comprises a carrier compound and at least one therapeutic agent, wherein the composition is embedded in the plurality of pores of the substrate;
wherein the device is configured such that, when the substrate is heated at or above a vaporization temperature of the carrier compound, the carrier compound is vaporized;
wherein, when the carrier compound is vaporized, the at least one therapeutic agent is released from the composition; and
wherein, as the carrier compound cools, the carrier compound is configured to condense around the at least one therapeutic agent, by which an aerosol is formed, the aerosol comprising the at least one therapeutic agent and the carrier compound.

### Claim 2 (depends on 1)

The device of claim 1, wherein the porous material of the substrate comprises a sintered metal and/or a sintered metal alloy, optionally, wherein the sintered metal and/or sintered metal alloy comprises stainless steel, a nickel-chrome alloy, tungsten, aluminum, and/or titanium.

### Claim 3 (depends on 1)

The device of claim 1, wherein the substrate comprises a first region, which has a first porosity, and a second region, which has a second porosity, the second porosity being different from the first porosity.

### Claim 4 (depends on 1)

The device of claim 1, wherein the substrate is formed via an additive manufacturing process.

### Claim 5 (depends on 1)

The device of claim 1, wherein the plurality of pores of the substrate comprises a total volume of internal void space, which is a same size or greater than a volume of the composition, the volume of the composition comprising a therapeutic dosage of the at least one therapeutic agent for administration to a subject.

### Claim 6 (depends on 1)

The device of claim 1, wherein the substrate comprises a disc or a cylinder.

### Claim 7 (depends on 1)

The device of claim 1, comprising a power source electrically connected to the substrate and configured to apply an electrical current to the substrate.

### Claim 8 (depends on 1)

The device of claim 1, wherein the vaporization temperature of the carrier compound is less than a vaporization temperature of each of the at least one therapeutic agent.

### Claim 9 (depends on 8)

The device of claim 8, wherein the vaporization temperature of the carrier compound is less than about 500° C.

### Claim 10 (depends on 1)

The device of claim 1, wherein the carrier compound comprises a phospholipid or lecithin.

### Claim 11 (depends on 1)

The device of claim 1, wherein the at least one therapeutic agent comprises a small molecule, a polynucleotide, a polypeptide, a nanoparticle, a viral vector, and/or a non-viral vector.

### Claim 12 (depends on 1)

The device of claim 1, wherein the at least one therapeutic agent comprises a therapeutic agent for treatment of a pulmonary disease or disorder, optionally, wherein the pulmonary disease or disorder comprises a bacterial infection, a viral infection, asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, emphysema, bronchitis, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, primary ciliary dyskinesia, and/or lung cancer.

### Claim 13 (depends on 1)

The device of claim 1, wherein the composition embedded in the plurality of pores of the substrate comprises one or more additives, optionally, the one or more additives comprising an absorption enhancer.

### Claim 14 (depends on 1)

A metered dose inhaler comprising at least one device according to claim 1, wherein the metered dose inhaler is configured for pulmonary delivery of the at least one therapeutic agent to a subject.

### Claim 15 (depends on 1)

A rodent nose-only exposure chamber comprising at least one device according to claim 1, wherein the exposure chamber is configured for pulmonary delivery of the at least one therapeutic agent to a rodent subject.

### Claim 16 (depends on 15)

The exposure chamber of claim 15, comprising an elutriator positioned in fluid communication between the at least one device and the exposure chamber.

### Claim 17

A method of producing an aerosol, the method comprising:
providing a device for generating the aerosol comprising:
a substrate comprising a porous material having a plurality of pores distributed throughout the substrate; and
a composition, which comprises a carrier compound and at least one therapeutic agent, wherein the composition is embedded in the plurality of pores of the substrate;
heating the substrate to a vaporization temperature of the carrier compound to produce a vaporized carrier compound and the at least one therapeutic agent, wherein formation of the vaporized carrier compound propels the at least one therapeutic agent out of the plurality of pores in the substrate; and
cooling, after vaporization, the vaporized carrier compound, which causes the vaporized carrier compound and the at least one therapeutic agent to condense, thereby forming an aerosol comprising the at least one therapeutic agent and the carrier compound.

### Claim 18 (depends on 17)

The method of claim 17, wherein the porous material of the substrate comprises a sintered metal and/or a sintered metal alloy, optionally, wherein the sintered metal and/or sintered metal alloy comprises stainless steel, a nickel-chrome alloy, tungsten, aluminum, and/or titanium.

### Claim 19 (depends on 17)

The method of claim 17, wherein the substrate comprises a first region, which has a first porosity, and a second region, which has a second porosity, the second porosity being different from the first porosity.

### Claim 20 (depends on 17)

The method of claim 17, wherein providing the device comprises forming the substrate via an additive manufacturing process.

### Claim 21 (depends on 17)

The method of claim 17, wherein the plurality of pores of the substrate comprises a total volume of internal void space, which is a same size or greater than a volume of the composition, the volume of the composition comprising a therapeutic dosage of the at least one therapeutic agent for administration to a subject.

### Claim 22 (depends on 17)

The method of claim 17, wherein providing the device comprises:
contacting the substrate with a volume of a solution and/or suspension, the solution and/or suspension comprising the carrier compound and the at least one therapeutic agent, wherein the solution and/or suspension comprises a high vapor pressure solvent, and wherein the solution and/or suspension comprises a surface tension, by which the solution and/or suspension flows into the plurality of pores of the substrate, optionally via capillary action; and
evaporating the high vapor pressure solvent, such that only the composition remains embedded in the plurality of pores of the substrate.

### Claim 23 (depends on 17)

The method of claim 17, wherein the carrier compound comprises a phospholipid or lecithin.

### Claim 24 (depends on 17)

The method of claim 17, wherein the at least one therapeutic agent comprises a therapeutic agent for treating a pulmonary disease or disorder.

### Claim 25 (depends on 17)

The method of claim 17, wherein heating the substrate comprises a resistive heating of the substrate via a flow of electric current through the substrate.

### Claim 26 (depends on 17)

The method of claim 17, wherein cooling the vaporized carrier compound comprises exposing the vaporized carrier compound to ambient air.

### Claim 27

A method of administering at least one therapeutic agent to a subject, the method comprising:
providing a device for generating an aerosol comprising:
a substrate comprising a porous material having a plurality of pores distributed throughout the substrate; and
a composition, which comprises a carrier compound and the at least one therapeutic agent, wherein the composition is embedded in the plurality of pores of the substrate;
heating the substrate to a vaporization temperature of the carrier compound to produce a vaporized carrier compound and the at least one therapeutic agent, wherein formation of the vaporized carrier compound propels the at least one therapeutic agent out of the plurality of pores in the substrate;
cooling, after vaporization, the vaporized carrier compound, which causes the vaporized carrier compound and the at least one therapeutic agent to condense, thereby forming an aerosol comprising the at least one therapeutic agent and the carrier compound; and
providing the aerosol to the subject via inhalation of the aerosol by the subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein the device is provided in a metered dose inhaler.
